Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer

Table 5

Comparative analysis according to the prognostic factors for MMP-9.

	Mean	Median	Min	Max
Endometroid/non-endometroid	7721.5/8909.8	7543.6/8823.3	7012.6/8002.3	8231/9567.6	0.04
G1/G2	5263/6789.2	5324.2/6881.2	4967.2/5122.5	5778.1/7657.7	0.061
G1/G3	5263/8782.1	5324.2/889.2	4967.2/6744.5	5778.1/989.0	0.02
FIGO I and II/FIGO III and IV	5433.1/9213.7	5367/9311.7	4977.2/7338.4	6877.2/10131.8	0.001
Vascular invasion (±)	5688.3/8672.9	5723.3/8721.5	5002.9/7112.4	5989.7/9881.7	0.004
Lymph vessels invasion (±)	6345.2/7187.2	6463.1/7132.2	4412.5/5323.9	7889.2/8999.3	0.07
Lymph nodes metastasis (±)	5998.1/9141.8	6021/9099.3	5121.9/7111	6781.9/10267	0.003
Infiltrate the myometrium superficial/deep	6891.3/9234.8	6631.4/9122.4	5899.6/7114.8	7346.8/10145.6	0.01